Mylan Apokyn Review Hampered By "Ubiquitous Use" Of Tigan In Trials
This article was originally published in The Pink Sheet Daily
FDA's Neuropharm division felt use of the older antiemetic in Parkinson's therapy trials posed "thorny problem" due to lack of chronic experience with Tigan and poorly documented concomitant use. FDA ultimately recommends concomitant antiemetic therapy in labeling, as well as a Phase IV study to determine the "actual necessity" of Tigan in combination with Apokyn.
You may also be interested in...
Bertek Apokyn (apomorphine) clears FDA April 20 for subcutaneous injection to treat "off" episodes of Parkinson's disease
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.